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Anumberofdifferent approaches have been usedto determine the catalytic selectivityofindividual human
enzymes toward procarcinogens. Studies with cytochrome P450 (P450) enzymes and glutathione S-trans-
ferases are summarized here, and recent work with pyrrolizidine alkaloids, aflatoxins, 4,4'-methylenebis(2-
chloroaniline), and ethyl carbamate is discussed. In some cases a single enzyme can catalyze both activation
and detoxication reactions ofa chemical. The purification and characterization ofhuman lung P4501A1 and
the development ofa noninvasive assay for human P4502E1 are also described.
Introduction
Most ofthe potentially genotoxic natural and synthetic
chemicals to which humans are exposed are not biolog-
ically active in themselves but require transformation to
reactive electrophiles (1). Metabolism ofxenobiotic chemi-
cals is complex, and various enzymes can activate or
detoxify compounds, depending on the particular situa-
tion. Even different enzymes of a family [e.g., the
cytochrome P450 (P450) group] can exert different influ-
ences by catalyzing different reactions. Levels of the
various enzymes knowntobeinvolvedinthemetabolismof
xenobiotics (2) often vary dramatically among individual
people, owing to both genetic and environmental influ-
ences (3,4). There is considerable precedent from experi-
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mental animal models to hypothesize that these dif-
ferences in enzyme levels may contribute to the overall
risk of an individual to a particular chemical. Thus, dis-
cernment of the catalytic selectivities of families of
enzymes is ofinterest for risk assessment. If a dominant
enzyme can be implicated in a particular reaction, then it
may be further considered as a potential risk factor. In
people with low levels of a particular enzyme, other
enzymes may participate but their enzymatic contribu-
tions will not be so important ifthe overall activity is low
(5).
Several in vitro approaches have been used in our
laboratories to identify which pro-carcinogens are
oxidized by individual human P450 enzymes and conju-
gated by human glutathione (GSH) S-transferases. The
rationale and somerecentstudies arepresentedhere,with
consideration of the further development of noninvasive
assays which can be used in molecular epidemiology bio-
marker studies with humans at risk (Table 1).
Rationale
At least five major approaches can be used in the
assigning of catalytic activities to particular P450 en-
zymes (5): a) Selective inhibitors maybe usedwith micro-
somes. The degree to which the activity is inhibited re-
flects the contributionofaparticularP450, iftheinhibitor
istrulyspecific. Thisapproachmayalsobeofusewithiso-GUENGERICH ETAL.
Table 1. Potential noninvasive assays for human P450s.
P450 Assay end point
1A2 Phenacetin O-deethylation
Caffeine 3-demethylation
2A6 Coumarin 7-hydroxylation
2C10 (also 2C8, 2C9) Tolbutamide hydroxylation
2D6 Debrisoquine 4-hydroxylation
Sparteine A2- and A6-oxidation
Dextromethorphan
N-Demethylation
2E1 Chlorzoxazone 6-hydroxylation
3A4 Nifedipine oxidation
Erythromycin N-demethylation
Dapsone N-hydroxylation
Lidocaine N-deethylation
Cortisol 63-hydroxylation
lated cells and in vivo. b) In a similar way inhibitory
antibodies can be used with microsomes. Of course, this
approach usually requires purification of an antigen to
raise the antibody; hence this strategy hasbeen employed
in a limited number of cases. c) The catalytic activity can
be measured in preparations (microsomes) derived from
different individuals and compared to a known reaction
catalyzed by a particular P450. The degree ofassociative
attribution (theparameterr2) shouldreflectthefractionof
the variation that can be ascribed to a relationship
between the two activities, usually interpreted as being
catalyzed by the same or similarly regulated enzymes. d)
Purified enzymes can be compared directly for catalytic
activity; however, someP450s donot appeartoretaintheir
full activities expressed in vivo after purification (6) and,
of course, comparison of the activities of a limited set of
enzymes has implications only among the set. e) A cDNA
can be expressed in an artificial vector system, and cata-
lytic activities can be assessed. Some eukaryotic cell lines
can be used, with transient or stable expression.
The latter two approaches are very useful for dis-
tinguishing the activities ofcloselyrelated enzymes, while
the first three procedures provide better estimates ofthe
extent to which a particular enzyme contributes to the
overall activity. Given the relative advantages and disad-
vantages of each technique, the most reliable conclusions
are derived with a battery of techniques as opposed to a
single one. Such knowledge is of course hypothetical in its
relevance and must be considered in light of findings in
vivo. A current list ofassignments ofmajor human P450s
involved in the activation ofprotoxicants and procarcino-
gens is presented in Table 2 (5).
Of course, many ofthese same general approaches can
be applied to studies with other enzymes, with some
modification; however, in no other case (other than the
P450s) has so extensive a menu oftechnical methods been
applied invitro, and oftenthenoninvasive assays are more
limited.
Pyrrolizidine Alkaloids
Senecionine has been studied as a prototype of the
pyrrolizidine alkaloids, which can be toxic and carcino-
genic in laboratory animals. Studies with rats have indi-
P450
Table 2. Protoxicants and procarcinogens activated by
human P450s (5).a
Protoxicants and procarcinogens
lAl Benzo[a]pyrene and other polycyclic hydrocarbons
2-Amino-l-methyl-6-phenylimidazo[4,5-b] pyridine
1A2 2-Acetylaminofluorene
2-Aminofluorene
2-Aminoanthracene
2-Amino-3-methylimidazo[4,5-pquinoline (IQ)
2-Amino-3,8-dimethylimidazo[4,5-fquinoline (MeIQ)
2-Amino-3,8-dimethylimidazo[4,5-flquinoxaline (MeIQx)
2-Amino-3,4,8-trimethylimidazo[4,5-]]quinoxaline (DiMeIQx)
2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole (Glu P-1)
3-Amino-1-methyl-5H-pyrido[4,3-b]indole (Trp P-2)
2-Aminodipyrido[1,2-a:3',2'-d]imidazole (Glu P-2)
2-Naphthylamine
4-Aminobiphenyl
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)
Acetaminophen
4-N-Nitroso(methylamino)-1-(3-pyridyl)-1-butanone (NNK)
2A6b N-Nitrosodiethylamine
4,4'-Methylenebis(2-chloroaniline) (MOCA)
2E1 N-Nitrosodimethylamine
N-Nitrosodiethylamine
N-Nitroso-N-methylbenzylamine
N-Nitrosomethylbutylamine
Benzene
Carbon tetrachloride
Chloroform
Methylene chloride
Trichloroethylene
Ethylene dichloride
Ethylene dibromide
1,2-Dichloropropane
Styrene
Vinyl chloride
Vinyl bromide
Acrylonitrile
Ethyl carbamate
Vinyl carbamate
Acetaminophen
3A4 Aflatoxin B1
Aflatoxin G1
Sterigmatocystin
Senecionine
7,8-Dihydroxy-7,8-dihydrobenzo[a]pyrene
9,10-Dihydroxy-9,10-dihydrobenzo[b]fluoranthene
3,4-Dihydroxy-3,4-dihydro-7,12-dimethylbenz[a]anthracene
6-Aminochrysene
tris-(2,3-Dibromopropyl)phosphate
1-Nitropyrene
4,4'-Methylenebis(2-chloroaniline) (MOCA)
17,B-Estradiol
aThepurposeofthistableistosummarize evidenceforamajorroleofa
single (human liver) P450 in the activation ofeach chemical. Of course,
otherP450s maycontribute to some extent, particularlyinindividuals in
whom the major enzyme is deficient. For further discussion, see Guen-
gerich and Shimada (5).
bP4502A6appearstomakesomecontributionbutdoesnotappeartobe
the dominant enzyme in either case.
cated that P450s catalyze both the formation ofpyrroles
and N-oxides, with the former considered to be an activa-
tion process and the latter a detoxication (8). In rats,
P4503A enzymes appear to be capable of forming both
pyrrolesandN-oxides (9). Inaddition,P4503A4appearsto
be the major human liver enzyme involved in both reac-
tions (10). As noted elsewhere (11), levels ofP4503A4 vary
considerablyamongindividuals.Thequestionmightthere-
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fore be raised as towhether higherlevels ofP450 3A4 are
detrimental or protective.
Aflatoxin B1 Oxidation
Aflatoxin B1 (AFB1) has severalfates ofrelevance toits
genotoxicity (Fig. 1). Our previous work led to the conclu-
sion that, although several forms of human P450 can
oxidize AFB1 to its 8,9-oxide, P4503A4 plays averymajor
role in this reaction, due to both the intrinsic rate and the
highlevels ofP4503A4thatcanexistinhumanliver(12,13).
In human fetal liver, the closely related P4503A7 appears
to play a dominant role (14). The results of others have
demonstrated that cDNA-expressed P4503A4 that has
high activity (per nanomole P450) and that antibodies
raised against P4503A enzymes are most inhibitory to
activation in human liver microsomes (7,15). Any role for
P4501A2 in bioactivation would appear to be minimal
because of the stimulation seen with 7,8-benzoflavone in
vitro (12,13)andthedemonstrated detoxifyinginfluenceof
rodent P4501A2 in vivo (13,16).
Studies in our laboratories have shown that when the
activationofAFB1 inhumanlivermicrosomes isexamined
bytrapping the GSH conjugate (in the presence ofmouse
livercytosol),theresultsareconsistentwiththoseinwhich
umu gene response or DNAN7-guanyl adducts are mea-
sured (12,13). For instance, GSH conjugate formation is
wellcorrelatedwithnifedipineoxidationindifferentmicro-
somal preparations (Fig. 2). AFB1 3a-hydroxylation (to
formAFQ1)was alsowellcorrelatedwithnifedipine oxida-
tion(r2 = 0.97) [seealso Forresteretal. (7)] andP4503A4
levels. Such ratios ofGSH conjugate andAFQ1 formation
(Fig. 2)were seen atAFB1 concentrations as low as2,uM;
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FIGURE 2. Correlation ofrates ofconversion ofaflatoxin B1 to aflatoxin
Q1 (0) oraflatoxinB1 8,9-oxidetrapped as itsglutathioneS-transferase
conjugate (U) with rates ofnifedipine oxidation in microsomal fractions
prepared from different human liver samples.
it appears that the Km for AFB1 epoxidation is approx-
imately 7 ,uM but that for AFB1 3-hydroxylation is much
higher. Even atthelowAFB1 concentration, theresults of
immunoinhibition, chemical inhibition, and correlation
experiments are consistent with the view that both AFB1
8,9-epoxidation and 3-hydroxylation are catalyzed pri-
marily by P4503A4. In microsomes, however, 7,8-benzo-
flavone stimulated epoxidation but inhibited 3-hydro-
0
0
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FIGURE 1. Scheme ofaflatoxin B1 metabolism.
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xylation. This phenomenon was also demonstrated with
purified yeastrecombinantP4503A4 (Table3) and isinter-
preted to reflect an allosteric effect on the enzyme which
has at least two potential transition states. At low AFB1
concentrations, below the Km, the ratio ofAFQ1: epoxide
formation should approach a constantvalue. Whether the
presence ofmoreP4503A4isdetrimental orbeneficial may
depend upon the in vitro assay, and the in vivo conse-
quences are not yet clear; however, a correlation between
urinary excretion of N7-guanyl AFB1 adducts and the
P4503A4 marker 6,B-hydroxycortisol (Table 1) has been
seen in studies in the Gambia.
GSH Conjugation of AFB1 8,9-Oxide
Inrats,biliaryexcretionoftheGSHconjugateis amajor
fate ofAFB1 (17). Mice are thought to be protected from
AFB1 by their high rates of enzymatic conjugation of
AFB1 8,9-oxide, and rats can be rendered resistant by
treatment with compounds that induce GSH S-trans-
ferases (18). In work done in our laboratories, it appears
that human liver cytosol has considerably less GSH
S-transferase activity towards synthetic AFB1 8,9-oxide
than rat liver cytosol. The consequences maybe ofsignifi-
cance in the evaluation ofstrategies for chemoprotection.
When a group ofpurified rat liver GSH S-transferases
was examined, a ,u-class enzyme (4-4) (19) and an a class
enzyme (1-1) were the most active. It is of considerable
interest that what appear to be two different ster-
eoisomeric forms of the GSH:AFB1 8,9-oxide conjugate
are formed by different enzymes in both rat and human
liver, and the a and ,u enzymes form different products. In
rats, the conjugation activity is induced by dithiolthione,
which induces a class enzymes (20). Ofthe human enzyme
classesexamined, theactivitiesvariedintheorderof > a
> rr. Therelevance ofthis specificity invivo remains to be
determined.
4,4'-Methylenebis(2-chloroaniline)
4,4'-Methylenebis(2-chloroaniline) (MOCA) can be car-
cinogenic in rodents and dogs and is ofconcern because of
its useinthecuringofpolyurethane.Although manyofthe
carcinogenic arylamines are oxidized to hydroxylamines,
mainlybyP4501A2 (Table2), MOCAhasbeenknowntobe
an exception (21). Recently, we purified P4502A6 from
human liver-the enzyme activates AFB1 but does not
appeartoplay animportantrole because ofits lowlevel [<
1% oftotal P450 (22)]. Purified P4502A6 catalyzed MOCA
... .E
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FIGURE 3. Immuno-inhibition of N-oxidation of 4,4'-methylenebis(2-
chloroaniline) (MOCA) in two human liver samples. Pre-immune anti-
body (0,D); anti-human P4503A4 (0,). Immunoglobulin G (IgG)
fractions were prepared from rabbit antisera.
N-hydroxylation, butanti-P4502A6inhibited < 20% ofthe
activity in human liver microsomes. Anti-P4503A4, how-
ever, could inhibit up to 75% of the microsomal activity
(Fig.3), andlevels ofcatalytic activitywerewellcorrelated
with nifedipine oxidation in different liver samples (r2 =
0.89). The P4503A4 inhibitor gestodene (23) could inhibit
at least half of the activity in some liver samples (with
inherentlyhighactivity)butwaslessinhibitoryin samples
with lower activity. Purified P4503A4 also catalyzed the
reaction.
P4502E1, Ethyl Carbamate, and
Chlorzoxazone
We and others have demonstrated thathuman P4502E1
can catalyze the oxidation of many small halogenated
hydrocarbons and vinyl monomers to reactive forms (24).
P4502E1 alsooxidizesethylcarbamate,ofinterestbecause
of its use in industry and its presence in fermented bev-
erages, tovinyl carbamate andthen to the epoxide (24,25).
Thepotentialriskofthese chemicals is still unclear, andit
may be useful to have a noninvasive assay of P4502E1,
since levels of the enzyme are known to vary and are
induced by ethanol consumption (26). Human and animal
P4502E1 enzymes are almost exclusively involved in
Table 3. Oxidation ofaflatoxin B1 (AFB1) by human P4503A4.
pmole Product formed min -1 (nmole P450)-la
P450 AFQ, AFB, 8,9-oxide:GSH conjugate
Yeast P450 285 9 70± 1
Yeast P4503A4 plus 141 13 260 ±24
20 F.M 7,8-benzoflavone
aYeast recombinant P4503A4 (0.2 ,uM) was incubated with rabbit liver NADPH-P450 reductase, L-a-dilauroyl-sn-glyceryl-3-phosphocholine, 0.1 M
potassium phosphatebuffer(pH 7.7), 50 ,uMAFB1, mouse livercytosol, and anNADPH-generating systemfor30min (liverP4503A4) or60 min (yeast
P4503A4). The amounts of AFQ1 and glutathione S-transferase:aflatoxin 8,9-oxide conjugate were determined by high-performance liquid chro-
matography.
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6-hydroxylation of the muscle relaxant drug chlorzox-
azone, at least as judged by studies in vitro (27). In
collaborative studies with G. R. Wilkinson at Vanderbilt
University, theusefulness ofthis reaction as ameasure of
P4502E1 invivoisbeingconsidered. Inthestudiesdoneto
date, the conversion to 6-hydroxychlorzoxazone in vivo is
inhibited by the P4502E1-selective agent disulfiram (24)
and increased in individuals after withdrawal from con-
sumption oflarge amounts ofethanol.
Lung P4501A1
Recently,whatappears tobeP4501A1 hasbeenpurified
to electrophoretic homogeneity from human lung micro-
somes. The total amount of spectrally detectable P450 in
human lung microsomes is very low, in the order of 10
pmole (P450)/mg protein. The properties of the enzyme
are consistent with a role in the metabolism of several
carcinogens. Insampleswithrelativelyhighratesofoxida-
tion of7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene, the role
of P4501A1 is a major one, but in samples with lower
activity its role appears to be less dominant. P4501A2
seems to be absent in human lung microsomes, asjudged
by several criteria. Another human lungmicrosomal P450
was partially purified, but its relevance in carcinogen
metabolism is unknown.
Conclusions
Anumberofapproaches canbeused tocharacterize the
selectivity ofindividual human enzymes in vitro, and our
current views regarding catalytic selectivity are summa-
rized here. In vitro approaches and observations on the
metabolism of drugs have led to the development of non-
invasive assays which can be used to phenotype indi-
viduals for enzymes hypothesized to contribute to the
metabolism of procarcinogens. In some cases, a single
enzyme can both activate and detoxify a single chemical,
and work in vivo will be required to evaluate the signifi-
cance ofvariation in enzyme levels.
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